|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
173,970,000 |
Market
Cap: |
4.87(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14 - $43.89 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipeline are: Acoramidis/AG10/BBP-265, a small molecule transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Infigratinib/BBP-831, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer for the treatment of congenital adrenal hyperplasia; and Encaleret, a small molecule antagonist of the calcium sensing receptor for the treatment of Autosomal Dominant Hypocalcemia Type 1.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
113,245 |
1,769,632 |
2,886,602 |
Total Sell Value |
$0 |
$4,697,014 |
$61,715,300 |
$73,415,196 |
Total People Sold |
0 |
3 |
6 |
6 |
Total Sell Transactions |
0 |
6 |
14 |
29 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kumar Neil |
CEO and President |
|
2020-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,129 |
4,694,209 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-11-16 |
4 |
D |
$44.33 |
$281,628 |
D/D |
(6,353) |
274,211 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-11-16 |
4 |
OE |
$0.00 |
$10,500 |
D/D |
22,813 |
280,564 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-11-16 |
4 |
AS |
$45.00 |
$450,000 |
D/D |
(10,000) |
267,751 |
|
29% |
|
Cook Jennifer E. |
Director |
|
2020-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,576 |
3,576 |
|
- |
|
Sinha Uma |
Chief Scientific Officer |
|
2020-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
469 |
16,460 |
|
- |
|
Mccormick Frank |
Chairman of Oncology |
|
2020-11-13 |
4 |
S |
$42.22 |
$4,275,769 |
D/D |
(100,000) |
1,200,468 |
|
-40% |
|
Turtle Cameron |
See Remarks |
|
2020-11-05 |
4 |
AS |
$42.05 |
$105,125 |
D/D |
(2,500) |
12,568 |
|
55% |
|
Turtle Cameron |
See Remarks |
|
2020-11-05 |
4 |
OE |
$17.00 |
$42,500 |
D/D |
2,500 |
15,068 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-11-02 |
4 |
AS |
$38.33 |
$383,558 |
D/D |
(10,000) |
267,751 |
|
81% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-11-02 |
4 |
OE |
$1.05 |
$10,500 |
D/D |
10,000 |
277,751 |
|
- |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-10-16 |
4 |
AS |
$41.00 |
$420,496 |
D/D |
(10,256) |
1,203,767 |
|
73% |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-10-16 |
4 |
OE |
$17.00 |
$174,352 |
D/D |
10,256 |
1,214,023 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-10-01 |
4 |
AS |
$38.29 |
$388,342 |
D/D |
(10,000) |
267,751 |
|
70% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-10-01 |
4 |
OE |
$0.28 |
$7,994 |
D/D |
10,000 |
277,751 |
|
- |
|
Turtle Cameron |
See Remarks |
|
2020-09-30 |
4 |
AS |
$37.59 |
$546,458 |
D/D |
(14,500) |
12,568 |
|
84% |
|
Turtle Cameron |
See Remarks |
|
2020-09-30 |
4 |
OE |
$0.16 |
$45,500 |
D/D |
14,500 |
27,068 |
|
- |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-09-30 |
4 |
AS |
$38.00 |
$380,000 |
D/D |
(10,000) |
1,203,767 |
|
84% |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-09-30 |
4 |
OE |
$17.00 |
$170,000 |
D/D |
10,000 |
1,213,767 |
|
- |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-09-29 |
4 |
AS |
$37.50 |
$682,500 |
D/D |
(18,200) |
1,203,767 |
|
84% |
|
Homcy Charles J |
Chairman of Pharmaceuticals |
|
2020-09-25 |
4 |
AS |
$36.68 |
$2,985,455 |
D/D |
(81,057) |
1,221,967 |
|
97% |
|
Turtle Cameron |
See Remarks |
|
2020-09-18 |
4 |
AS |
$42.01 |
$105,024 |
D/D |
(2,500) |
12,568 |
|
36% |
|
Turtle Cameron |
See Remarks |
|
2020-09-18 |
4 |
OE |
$17.00 |
$42,500 |
D/D |
2,500 |
15,068 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-09-18 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
267,751 |
|
36% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-09-18 |
4 |
OE |
$0.16 |
$2,212 |
D/D |
10,000 |
277,751 |
|
- |
|
288 Records found
|
|
Page 7 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|